These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26749719)

  • 21. Ivacaftor potentiation of multiple CFTR channels with gating mutations.
    Yu H; Burton B; Huang CJ; Worley J; Cao D; Johnson JP; Urrutia A; Joubran J; Seepersaud S; Sussky K; Hoffman BJ; Van Goor F
    J Cyst Fibros; 2012 May; 11(3):237-45. PubMed ID: 22293084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.
    Sawicki GS; McKone EF; Pasta DJ; Millar SJ; Wagener JS; Johnson CA; Konstan MW
    Am J Respir Crit Care Med; 2015 Oct; 192(7):836-42. PubMed ID: 26132840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New treatments targeting the basic defects in cystic fibrosis.
    Fajac I; Wainwright CE
    Presse Med; 2017 Jun; 46(6 Pt 2):e165-e175. PubMed ID: 28554723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
    Antoniu SA
    Expert Opin Investig Drugs; 2011 Mar; 20(3):423-5. PubMed ID: 21303308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.
    Magne F; Durupt S; Nove-Josserand R; Bey-Omar F; Laoust L; Cottin V; Durieu I; Reynaud Q
    J Cyst Fibros; 2017 Jan; 16(1):89-90. PubMed ID: 27810230
    [No Abstract]   [Full Text] [Related]  

  • 26. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis.
    Grasemann H; Gonska T; Avolio J; Klingel M; Tullis E; Ratjen F
    J Cyst Fibros; 2015 Nov; 14(6):727-32. PubMed ID: 26168933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ivacaftor in a young boy with the rare gating mutation S549R--use of lung clearance index to track progress: a case report.
    Lenherr N; Lurà M; Trachsel D; Latzin P; Hammer J
    BMC Pulm Med; 2015 Oct; 15():123. PubMed ID: 26474553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A combination therapy for cystic fibrosis.
    Brodsky JL; Frizzell RA
    Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ivacaftor in a G551D homozygote with cystic fibrosis.
    Harrison MJ; Murphy DM; Plant BJ
    N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
    [No Abstract]   [Full Text] [Related]  

  • 31. The Role of Ivacaftor in Severe Cystic Fibrosis in a Patient With the R117H Mutation.
    Ronan NJ; Fleming C; O'Callaghan G; Maher MM; Murphy DM; Plant BJ
    Chest; 2015 Sep; 148(3):e72-e75. PubMed ID: 26324139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Excitement mounts for first disease-modifying cystic fibrosis drugs.
    Opar A
    Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
    [No Abstract]   [Full Text] [Related]  

  • 33. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
    Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A
    J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A safety evaluation of ivacaftor for the treatment of cystic fibrosis.
    McColley SA
    Expert Opin Drug Saf; 2016 May; 15(5):709-15. PubMed ID: 26968005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promising new era dawns for cystic fibrosis treatment.
    Corbyn Z
    Lancet; 2012 Apr; 379(9825):1475-6. PubMed ID: 22530244
    [No Abstract]   [Full Text] [Related]  

  • 36. [News in cystic fibrosis].
    Delaisi B
    Rev Pneumol Clin; 2013 Aug; 69(4):225-8. PubMed ID: 23856023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation.
    Seliger VI; Rodman D; Van Goor F; Schmelz A; Mueller P
    J Cyst Fibros; 2013 Dec; 12(6):706-13. PubMed ID: 23628510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lung clearance index response in patients with CF with class III CFTR mutations.
    Kane M; Gonska T; Jensen R; Avolio J; Klingel M; Stanojevic S; Ratjen F
    Thorax; 2016 May; 71(5):476-7. PubMed ID: 26944510
    [No Abstract]   [Full Text] [Related]  

  • 39. Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry.
    Sawicki GS; Dasenbrook E; Fink AK; Schechter MS
    Ann Am Thorac Soc; 2015 Aug; 12(8):1146-52. PubMed ID: 26073026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
    van Koningsbruggen-Rietschel S; Naehrlich L
    Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.